Cargando…
Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination
BACKGROUND: The cost-effectiveness of universal rotavirus (RV) vaccination is controversial in developed countries. As a result, RV vaccination programs do not currently exist in most European countries. Hospitalization is the main driver of RV disease costs, and prematurity, low birth weight (LBW)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665442/ https://www.ncbi.nlm.nih.gov/pubmed/23622110 http://dx.doi.org/10.1186/1741-7015-11-112 |
_version_ | 1782271249453416448 |
---|---|
author | Bruijning-Verhagen, Patricia Mangen, Marie-Josée J Felderhof, Mariet Hartwig, Nico G van Houten, Marlies Winkel, Léon de Waal, Wouter J Bonten, Marc JM |
author_facet | Bruijning-Verhagen, Patricia Mangen, Marie-Josée J Felderhof, Mariet Hartwig, Nico G van Houten, Marlies Winkel, Léon de Waal, Wouter J Bonten, Marc JM |
author_sort | Bruijning-Verhagen, Patricia |
collection | PubMed |
description | BACKGROUND: The cost-effectiveness of universal rotavirus (RV) vaccination is controversial in developed countries. As a result, RV vaccination programs do not currently exist in most European countries. Hospitalization is the main driver of RV disease costs, and prematurity, low birth weight (LBW) and underlying medical conditions have been associated with RV hospitalization and complications. We investigated the cost-effectiveness of targeted RV vaccination of high-risk infants and universal RV vaccination versus no vaccination. METHODS: Disease burden, mortality and healthcare costs of RV hospitalization for children with and without prematurity, LBW and congenital pathology were quantified in two hospital-based observational studies in the Netherlands. Cost-effectiveness analysis was based on an age-structured stochastic multi-cohort model of the Dutch population comparing universal RV vaccination and targeted vaccination of high-risk infants to no vaccination. The primary endpoint was the incremental cost-effectiveness ratio (ICER), with a threshold of €35,000/quality-adjusted life year (QALY) from the healthcare provider perspective. Sensitivity analyses included vaccine price and coverage, herd-immunity and QALY losses. RESULTS: A total of 936 children with RV infection were included. Prematurity, LBW and congenital pathology were associated with increased risks of RV hospitalization (relative risks (RR) ranging from 1.6 to 4.4), ICU admission (RR ranging from 4.2 to 7.9), prolonged hospital stay (1.5 to 3.0 excess days) and higher healthcare costs (€648 to €1,533 excess costs). Seven children succumbed due to RV complications, all belonging to the high-risk population. Targeted RV vaccination was highly cost-effective and potentially cost-saving from the healthcare provider perspective with ICERs below €20,000/QALY in all scenarios with total (undiscounted) annual healthcare costs between -€0.1 and €0.5 million/year. Results were most sensitive to mortality rates, but targeted vaccination remained highly cost-effective up to reductions of 90% compared to observed mortality. Universal RV vaccination was not considered cost-effective (mean ICER: €60,200/QALY) unless herd-immunity and caretaker QALY losses were included and vaccine prices were €60 at most (mean ICER: €21,309/QALY). CONCLUSION: We recommend targeted RV vaccination for high-risk infants in developed countries. |
format | Online Article Text |
id | pubmed-3665442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36654422013-06-05 Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination Bruijning-Verhagen, Patricia Mangen, Marie-Josée J Felderhof, Mariet Hartwig, Nico G van Houten, Marlies Winkel, Léon de Waal, Wouter J Bonten, Marc JM BMC Med Research Article BACKGROUND: The cost-effectiveness of universal rotavirus (RV) vaccination is controversial in developed countries. As a result, RV vaccination programs do not currently exist in most European countries. Hospitalization is the main driver of RV disease costs, and prematurity, low birth weight (LBW) and underlying medical conditions have been associated with RV hospitalization and complications. We investigated the cost-effectiveness of targeted RV vaccination of high-risk infants and universal RV vaccination versus no vaccination. METHODS: Disease burden, mortality and healthcare costs of RV hospitalization for children with and without prematurity, LBW and congenital pathology were quantified in two hospital-based observational studies in the Netherlands. Cost-effectiveness analysis was based on an age-structured stochastic multi-cohort model of the Dutch population comparing universal RV vaccination and targeted vaccination of high-risk infants to no vaccination. The primary endpoint was the incremental cost-effectiveness ratio (ICER), with a threshold of €35,000/quality-adjusted life year (QALY) from the healthcare provider perspective. Sensitivity analyses included vaccine price and coverage, herd-immunity and QALY losses. RESULTS: A total of 936 children with RV infection were included. Prematurity, LBW and congenital pathology were associated with increased risks of RV hospitalization (relative risks (RR) ranging from 1.6 to 4.4), ICU admission (RR ranging from 4.2 to 7.9), prolonged hospital stay (1.5 to 3.0 excess days) and higher healthcare costs (€648 to €1,533 excess costs). Seven children succumbed due to RV complications, all belonging to the high-risk population. Targeted RV vaccination was highly cost-effective and potentially cost-saving from the healthcare provider perspective with ICERs below €20,000/QALY in all scenarios with total (undiscounted) annual healthcare costs between -€0.1 and €0.5 million/year. Results were most sensitive to mortality rates, but targeted vaccination remained highly cost-effective up to reductions of 90% compared to observed mortality. Universal RV vaccination was not considered cost-effective (mean ICER: €60,200/QALY) unless herd-immunity and caretaker QALY losses were included and vaccine prices were €60 at most (mean ICER: €21,309/QALY). CONCLUSION: We recommend targeted RV vaccination for high-risk infants in developed countries. BioMed Central 2013-04-26 /pmc/articles/PMC3665442/ /pubmed/23622110 http://dx.doi.org/10.1186/1741-7015-11-112 Text en Copyright © 2013 Bruijning-Verhagen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bruijning-Verhagen, Patricia Mangen, Marie-Josée J Felderhof, Mariet Hartwig, Nico G van Houten, Marlies Winkel, Léon de Waal, Wouter J Bonten, Marc JM Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination |
title | Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination |
title_full | Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination |
title_fullStr | Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination |
title_full_unstemmed | Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination |
title_short | Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination |
title_sort | targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665442/ https://www.ncbi.nlm.nih.gov/pubmed/23622110 http://dx.doi.org/10.1186/1741-7015-11-112 |
work_keys_str_mv | AT bruijningverhagenpatricia targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination AT mangenmariejoseej targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination AT felderhofmariet targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination AT hartwignicog targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination AT vanhoutenmarlies targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination AT winkelleon targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination AT dewaalwouterj targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination AT bontenmarcjm targetedrotavirusvaccinationofhighriskinfantsalowcostandhighlycosteffectivealternativetouniversalvaccination |